Opinion|Videos|April 14, 2025
INTRIGUE Trial: Key Findings in Second-Line Setting
Experts discuss the key findings from the INTRIGUE trial comparing ripretinib to sunitinib in the second-line setting, focusing on efficacy endpoints like progression-free survival (PFS) and PFS on next line of therapy, and interpret the patient-reported outcome (PRO) and tolerability data reported in the study.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Please walk us through the key findings from the
INTRIGUE trial comparing ripretinib to sunitinib in the second-line setting. What were the key efficacy end points evaluated in this study, and how did ripretinib perform compared to sunitinib on measures like PFS and PFS on next line of therapy? How do you interpret thePRO and tolerability data reported from INTRIGUE?
Advertisement
Related to this article
The top 5 OncLive TV videos of the week cover insights in ovarian cancer, breast cancer, head and neck cancer, pancreatic cancer, and follicular lymphoma.
Adanma Ayanambakkam, MD, MS, discusses findings from the FIT-001 trial of darlifarnib plus cabozantinib in RCC.
UroGen submitted an NDA for UGN-103 in recurrent NMIBC, T-DXd improved PFS in first-line HER2-mutant lung cancer, and more.
In a phase 1/2 study, the LSD1 inhibitor bomedemstat reduced spleen volume, improved symptoms, and lowered driver mutation burden in patients with advanced myelofibrosis.
Neeta Somaiah, MD, discusses the significance of the Peak study and what an approval of bezuclastinib plus sunitinib would mean for GIST.
Sara Nunnery, MD, MSCI, and Irene M. Kang, MD, discuss toxicity and monitoring considerations for the use of ADCs in metastatic TNBC.
The NMPA accepted the NDA for the PD-L1/4-1BB–directed bispecific antibody opamtistomig in previously treated advanced extrapulmonary NEC.
Obesity can weaken the immune system and lead to disease progression, but Roswell Park experts revealed that exercise may reverse that effect.
Advertisement
Advertisement
Trending on OncLive
1
ASCO Issues First Guideline on ctDNA Testing in Solid Tumors and Lymphoma
2
Intismeran Autogene Plus Pembrolizumab Meets RFS and DMFS End Points in Resected Stage IIB-IV Melanoma
3
The OncFive: Top Oncology Articles for the Week of 8/16
4
ESMO Guidelines Express Update Recommends Daraxonrasib for RAS G12–Mutated Metastatic PDAC
5